Kissei Pharmaceutical Co., Ltd.
KSPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.16 | 1.76 | -0.59 | 0.06 |
| FCF Yield | 0.96% | -2.24% | -0.09% | -0.03% |
| EV / EBITDA | 6.53 | 7.24 | 39.20 | 51.45 |
| Quality | ||||
| ROIC | 1.94% | 1.28% | -1.00% | -1.33% |
| Gross Margin | 49.89% | 49.41% | 0.33% | 0.36% |
| Cash Conversion Ratio | 0.42 | -0.15 | -0.63 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.38% | 4.95% | -0.75% | 381.46% |
| Free Cash Flow Growth | 142.48% | -3,251.45% | -204.41% | 70.41% |
| Safety | ||||
| Net Debt / EBITDA | -1.18 | -1.15 | 0.38 | 0.60 |
| Interest Coverage | 274.90 | 223.17 | -56.45 | -60.96 |
| Efficiency | ||||
| Inventory Turnover | 1.77 | 1.45 | 0.01 | 0.02 |
| Cash Conversion Cycle | 290.56 | 342.80 | 23,451.80 | 18,313.93 |